Fast Facts
Company Overview
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 10,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including ophthalmology, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.
Number of Employees
Allergan employs approximately 10,000 people worldwide and operates world-class research and development facilities and state-of-the-art manufacturing plants. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities, with a presence in more than 100 countries.
Year Founded
1950
Corporate Headquarters
Irvine, California
Chairman of the Board, President & CEO
David E. I. Pyott
Executive Committee
David E. I. Pyott
James F. Barlow
Raymond H. Diradoorian
Jeffrey L. Edwards
David J. Endicott
Julian S. Gangolli
Douglas S. Ingram
Arnold A. Pinkston
Scott D. Sherman
Scott M. Whitcup, M.D.
Key Financials
For the quarter ended December 31, 2011
- Allergan reported $1,382.8 million total product net sales. Total product net sales increased 7.2 percent compared to total product net sales in the fourth quarter of 2010. On a constant currency basis, total product net sales increased 8.2 percent compared to total product net sales in the fourth quarter of 2010.
- Total specialty pharmaceuticals net sales increased 8.9 percent, or 10.1 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2010.
- Total medical devices net sales increased 1.0 percent, or 0.4 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2010.
For the quarter ended September 30, 2011
- Allergan reported $1,311.1 million total product net sales. Total product net sales increased 10.0 percent compared to total product net sales in the third quarter of 2010. On a constant currency basis, total product net sales increased 7.2 percent compared to total product net sales in the third quarter of 2010.
- Total specialty pharmaceuticals net sales increased 10.1 percent, or 7.5 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2010.
- Total medical devices net sales increased 9.2 percent, or 5.6 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2010.
For the quarter ended June 30, 2011
- Allergan reported $1,400.4 million total product net sales. Total product net sales increased 13.7 percent compared to total product net sales in the second quarter of 2010. On a constant currency basis, total product net sales increased 9.6 percent compared to total product net sales in the second quarter of 2010.
- Total specialty pharmaceuticals net sales increased 14.0 percent, or 10.1 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2010.
- Total medical devices net sales increased 12.2 percent, or 7.0 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2010.
For the quarter ended March 31, 2011
- Allergan reported $1,252.8 million total product net sales. Total product net sales increased 13.3 percent compared to total product net sales in the first quarter of 2010. On a constant currency basis, total product net sales increased 12.2 percent compared to total product net sales in the first quarter of 2010.
- Total specialty pharmaceuticals net sales increased 13.3 percent, or 12.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2010.
- Total medical devices net sales increased 13.0 percent, or 11.9 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2010.
For the quarter ended December 31, 2010
- Allergan reported $1,290.1 million total product net sales. Total product net sales increased 6.9 percent compared to total product net sales in the fourth quarter of 2009. On a constant currency basis, total product net sales increased 7.4 percent compared to total product net sales in the fourth quarter of 2009.
- Total specialty pharmaceuticals net sales increased 6.9 percent, or 7.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2009.
- Total medical devices net sales increased 7.1 percent, or 7.9 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2009.
For the quarter ended September 30, 2010
- Allergan reported $1,192.0 million total product net sales. Total product net sales increased 5.7 percent compared to total product net sales in the third quarter of 2009. On a constant currency basis, total product net sales increased 6.3 percent compared to total product net sales in the third quarter of 2009.
- Total specialty pharmaceuticals net sales increased 6.9 percent, or 7.3 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2009.
- Total medical devices net sales increased 7.1 percent, or 7.9 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2009.
For the quarter ended June 30, 2010
- Allergan reported $1,231.7 million total product net sales. Total product net sales increased 10.1 percent compared to total product net sales in the second quarter of 2009. On a constant currency basis, total product net sales increased 9.3 percent compared to total product net sales in the second quarter of 2009.
- Total specialty pharmaceuticals net sales increased 10.0 percent, or 9.2 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2009.
- Total medical devices net sales increased 10.6 percent, or 10.0 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2009.
For the quarter ended March 31, 2010
- Allergan reported $1,105.8 million total product net sales. Total product net sales increased 11.2 percent compared to total product net sales in the first quarter of 2009. On a constant currency basis, total product net sales increased 6.9 percent compared to total product net sales in the first quarter of 2009.
- Total specialty pharmaceuticals net sales increased 9.7 percent, or 5.6 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2009.
- Total medical devices net sales increased 18.4 percent, or 13.4 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2009.
2009
- For the year ending 2009, total product net sales totaled $4,447.6 million, a 2.5 percent increase over 2008.